查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
克隆和誘變市場-全球行業規模,趨勢,機會和預測,2018-2028 年,按基因型,按產品類型,按技術,按應用,按最終用戶,按地區,按競爭
市場調查報告書
商品編碼
1255234

克隆和誘變市場-全球行業規模,趨勢,機會和預測,2018-2028 年,按基因型,按產品類型,按技術,按應用,按最終用戶,按地區,按競爭

Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Gene Type, By Product Type, By Technique, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球克隆和誘變市場預計在預測期內將出現顯著增長。

這可能是由於克隆方法在各種遺傳應用中的擴展，例如生殖克隆和基因克隆。此外，克隆和誘變市場受到各種需要克隆和誘變試劑盒的新產品發布以及政府機構投資於乾細胞研究以在世界各個地區開發新療法和療法的推動。對克隆和誘變的需求已經顯著增加此外，全球越來越多的易患各種疾病和肥胖的老年人口也有望進一步增加對克隆和誘變的需求，推動市場增長到 2028 年。此外，人們越來越意識到基因治療和診斷的好處，以及增加治療慢性病的醫療保健支出，預計將在預測期內進一步推動克隆和誘變市場。到 2022 年，估計美國將有 66,470 人（48,520 名男性和 17,950 名女性）被診斷出患有頭頸癌。

癌症和其他慢性病研發活動的增加將推動市場增長

為開發癌症療法和其他罕見疾病而增加的克隆和誘變研發預計將在預測期內推動市場利潤豐厚的增長。政府機構正在尋求能為他們帶來更高回報的發達基礎設施。可用於癌症治療的各種創新和倫理上可接受的治療方式，以及不斷增加的新產品開發，預計將在未來幾年推動市場增長。2020 年 5 月，Takara Bio 宣布與 AGC Biologics 合作，兩家公司的業務將合作開發針對 COVID-19 的預防性 DNA 疫苗，AGC Biologics 將為該疫苗生產質粒 DNA 中間體。AGC Biologics 已決定製造針對 COVID-19 的預防性 DNA 疫苗，以應對越來越多的由歐盟委員會和日本醫學研究與開發機構等公共基金資助的研究。到 2020 年，估計美國將診斷出 276,480 例浸潤性乳腺癌新病例和 48,530 例原位乳腺癌新病例。越來越多的基因克隆以合成抗生素、激素、維生素等以治療囊性纖維化等正在推動市場的增長。

政府機構增加投資推動市場增長

預計將創造市場有利增長的關鍵因素包括治療技術的進步，以及基因合成和克隆服務的有利融資場景，其次是研究、亞克隆服務以及市場協同效應的增強等等。預計在預測期內，對基因治療的需求不斷增加，新型和先進的 DNA 克隆技術的採用不斷增加，預計將產生利潤豐厚的市場增長。

近期發展狀況

  • 2021 年 1 月，Codex DNA 與Pfizer簽訂了一項早期研究合作和許可協議，根據該協議，Pfizer將能夠使用 CodexDNA 的新型□促 DNA 合成技術來研發基於 mRNA 的疫苗和生物治療藥物。負責進一步開發的技術。
  • 2020年5月，GenScript剛剛推出GMP單鍊和雙鏈DNA服務，支持基因和細胞療法的發展。該公告強調了 GenScript 在整個 IND 和臨床階段支持非病毒細胞療法開發的承諾。

可定制

鑑於市場數據，TechSci Research 可根據公司的具體需求提供定制服務。該報告可以定制為：

關於我們

  • 對其他市場參與者（最多 5 個）的詳細分析和概況分析。

目錄

第一章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年
    • 主要市場細分

第二章研究方法論

  • 研究目標
  • 基線調查法
  • 重點行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第三章執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第四章VOC（客戶之聲）

第五章克隆和誘變的全球市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型（標準型/複雜型）
    • 按產品類型（克隆試劑盒/致突變試劑盒）
    • 按方法（Topo PCR 克隆、Blunt End 克隆、無縫克隆、定點誘變等）
    • 按應用（基因合成、基因表達、基因治療、疫苗研究等）
    • 按最終用戶（製藥/生物技術公司、學術/研究機構等）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按地區

第六章北美克隆誘變市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按國家
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

七、歐洲克隆誘變市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

八、亞太克隆誘變市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第九章南美克隆誘變市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章中東和非洲克隆和誘變市場展望

  • 市場規模/預測
    • 按金額
  • 市場份額及預測
    • 按基因型
    • 按產品類型
    • 通過技術
    • 按申請
    • 按最終用戶
    • 按國家
  • MEA：國家分析
    • 南非
    • 沙特阿拉伯
    • 阿聯酋

第十一章市場動態

  • 促進者
  • 任務

第十二章市場趨勢與發展

  • 最近的發展
  • 嘛
  • 產品展示

第13章競爭格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Agilent Technologies, Inc.
    • Eurofins Scientific SE
    • Sartorius AG
    • Collecta, Inc.
    • Codex DNA Inc.
    • Lonza Group AG
    • Charles River Laboratories International, Inc.
    • TransGene Biotech Co. Ltd.
    • Takara Bio, Inc.
    • Thermo Fisher Scientific Inc.

第十四章戰略建議

簡介目錄
Product Code: 14421

The Global Cloning & Mutagenesis Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing cloning approaches in different genetic applications like reproductive cloning and genetic cloning. Additionally, various new product launches in the cloning and mutagenesis market, which will demand cloning and mutagenesis kits, along with government organizations investing in stem cell research for the development of new treatments and therapy, have significantly increased the demand for cloning and mutagenesis across different parts of the globe. Additionally, the growing geriatric population across the globe, which is susceptible to different kinds of diseases and obesity, is further expected to increase the demand for cloning and mutagenesis, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on chronic disease treatment across the globe, are further expected to support the cloning and mutagenesis market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.

Increasing Research and Development Activities in Cancer and Other Chronic Disorders Fueling the Market Growth

Increasing research and development regarding cloning and mutagenesis for the development of cancer therapies and other rare disorders is expected to create lucrative growth in the market during the forecast period. Government organizations are focusing on developed infrastructure with higher profits. Different types of innovative and ethically accepted therapies available for cancer therapy, along with the increasing development of new products, are expected to boost market growth over the years. In May 2020, Takara Bio announced a collaboration with AGC Biologics, and their businesses would collaborate on a prophylactic DNA vaccine against COVID-19 with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. . as public-funded research is getting a boost from bodies such as the European Commission and the Japan Agency for Medical Research and Development. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer. The increasing cloning of genes for the synthesis of antibiotics, hormones, and vitamins, among others, for the treatment of issues such as cystic fibrosis is propelling the market growth.

Increasing Investment by Government Organizations is Driving the Market Growth

Important factors which are expected to create lucrative growth in the market include a favorable funding scenario for gene synthesis and cloning services, along with technological advancement in the treatment, followed by research, subcloning services, and rising synergistic activities in the market. Increasing demand for gene therapy and growing adoption of novel and advanced DNA cloning technologies are expected to create a lucrative growth of the market during the forecast period.

Market Segmentation

Global cloning & mutagenesis market can be segmented by gene type, product type, technique, application, end-user, and by region. Based on gene type, the market can be divided into Standard and Complex. Based on product type, the market can be divided into Cloning Kits and Mutagenesis Kits. Based on technique, the market can be segmented into Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, and Others. Based on application, the market can be segmented into Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, and Others. Based on the end user, the market can be differentiated into Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America.

Market Players

Agilent Technologies, Inc., Eurofins Scientific SE, Sartorius AG, Collecta, Inc., Codex DNA Inc., Lonza Group AG, Charles River Laboratories International, Inc., TransGene Biotech Co. Ltd., Takara Bio, Inc., Thermo Fisher Scientific Inc. are some of the leading players operating in the Global Cloning & Mutagenesis Market.

Recent Developments

  • In Jan 2021, Codex DNA and Pfizer signed an early access collaboration and licensing agreement, which will allow Pfizer to use CodexDNA's novel enzymatic DNA synthesis technology in its research and development of mRNA-based vaccines and biotherapies and it will be responsible for further developing the technology.
  • In May 2020, GenScript just launched a GMP single-strand and double-strand DNA service to aid in the growth of gene and cell therapies. The announcement highlights GenScript's commitment to assisting entire non-viral cell therapy development through the IND-enabling and clinical stages.

Report Scope

In this report, global cloning & mutagenesis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cloning & Mutagenesis Market, By Gene Type:

  • Standard
  • Complex

Cloning & Mutagenesis Market, By Product Type:

  • Cloning Kits
  • Mutagenesis Kits

Cloning & Mutagenesis Market, By Technique:

  • Topo PCR Cloning
  • Blunt End Cloning
  • Seamless Cloning
  • Site-Directed Mutagenesis
  • Others

Cloning & Mutagenesis Market, By Application:

  • Gene Synthesis
  • Gene Expression
  • Gene Therapy
  • Vaccine Research
  • Others

Cloning & Mutagenesis Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Others

Cloning & Mutagenesis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cloning & Mutagenesis Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cloning & Mutagenesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Gene Type (Standard v/s Complex)
    • 5.2.2. By Product Type (Cloning Kits v/s Mutagenesis Kits)
    • 5.2.3. By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others)
    • 5.2.4. By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Gene Type
    • 5.3.2. By Product Type
    • 5.3.3. By Technique
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Cloning & Mutagenesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Gene Type
    • 6.2.2. By Product Type
    • 6.2.3. By Technique
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cloning & Mutagenesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Gene Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Technique
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Cloning & Mutagenesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Gene Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Technique
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Cloning & Mutagenesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Gene Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Technique
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Cloning & Mutagenesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Gene Type
    • 7.2.2. By Product Type
    • 7.2.3. By Technique
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cloning & Mutagenesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Gene Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Germany Cloning & Mutagenesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Gene Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Cloning & Mutagenesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Gene Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Cloning & Mutagenesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Gene Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Technique
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Cloning & Mutagenesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Gene Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Technique
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Cloning & Mutagenesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Gene Type
    • 8.2.2. By Product Type
    • 8.2.3. By Technique
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cloning & Mutagenesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Gene Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Cloning & Mutagenesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Gene Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Cloning & Mutagenesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Gene Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Cloning & Mutagenesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Gene Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Cloning & Mutagenesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Gene Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Cloning & Mutagenesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Gene Type
    • 9.2.2. By Product Type
    • 9.2.3. By Technique
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cloning & Mutagenesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Gene Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Cloning & Mutagenesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Gene Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Cloning & Mutagenesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Gene Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Cloning & Mutagenesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Gene Type
    • 10.2.2. By Product Type
    • 10.2.3. By Technique
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cloning & Mutagenesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Gene Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Cloning & Mutagenesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Gene Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Cloning & Mutagenesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Gene Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Agilent Technologies, Inc.
    • 13.6.2. Eurofins Scientific SE
    • 13.6.3. Sartorius AG
    • 13.6.4. Collecta, Inc.
    • 13.6.5. Codex DNA Inc.
    • 13.6.6. Lonza Group AG
    • 13.6.7. Charles River Laboratories International, Inc.
    • 13.6.8. TransGene Biotech Co. Ltd.
    • 13.6.9. Takara Bio, Inc.
    • 13.6.10. Thermo Fisher Scientific Inc.

14. Strategic Recommendations